<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943575</url>
  </required_header>
  <id_info>
    <org_study_id>20214</org_study_id>
    <nct_id>NCT04943575</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)</brief_title>
  <official_title>Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PPC Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Citruslabs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PPC Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized-controlled interventional clinical trial to evaluate the effectiveness of EZC&#xD;
      Pak &amp; EZC Pak+D for the treatment of the common cold and/or a URI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized-controlled interventional treatment study with three arms of comparable&#xD;
      demographics to evaluate the efficacy of PPC Pharmaceuticals EZC Pak (&amp; EZC Pak+D) to improve&#xD;
      the severity and duration of the common cold or a URI in individuals. It is hypothesized that&#xD;
      study participants will experience a positive impact on the duration and severity of their&#xD;
      cold/URI while using EZC Pak (&amp;EZC Pak+D). The second study objective is to examine if&#xD;
      patients are accepting the test product as an alternative to antibiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective: Reduction in severity of common cold symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>The primary objective of this study is to understand if EZC Pak (and EZC Pak +D) reduces the severity and duration of an upper respiratory illness (URI) compared to a placebo. The study uses a scale of 1-4 (no symptoms to severe symptoms) to assess the effectiveness of the intervention.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EZC Pak</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EZC Pak+D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EZC Pak</intervention_name>
    <description>After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.</description>
    <arm_group_label>Intervention 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EZC Pak +D</intervention_name>
    <description>After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.</description>
    <arm_group_label>Intervention 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female over 18 years old&#xD;
&#xD;
          -  Must be in good health (don't report any medical conditions asked in the screening&#xD;
             questionnaire)&#xD;
&#xD;
          -  Seeking OTC remedies to reduce the severity and duration of their common cold&#xD;
             symptoms, when they arise&#xD;
&#xD;
          -  Must have a thermometer at home&#xD;
&#xD;
          -  Must have a blood pressure monitor at home&#xD;
&#xD;
          -  Ideally, uses one of the following devices: Apple Watch, Oura Ring, FitBit, other&#xD;
             fitness trackers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to try the test product for their cold&#xD;
&#xD;
          -  Has any of the following medical conditions:&#xD;
&#xD;
               -  ragweed or daisy allergy&#xD;
&#xD;
               -  chronic seasonal allergies&#xD;
&#xD;
               -  liver disease&#xD;
&#xD;
               -  autoimmune or connective tissue disorder (e.g., rheumatoid arthritis, lupus,&#xD;
                  multiples sclerosis, HIV)&#xD;
&#xD;
               -  alcohol consumption more than 7 drinks per week, or more than 3 drinks per&#xD;
                  occasion&#xD;
&#xD;
               -  IV drug use&#xD;
&#xD;
               -  renal disease&#xD;
&#xD;
               -  females that are pregnant, want to become pregnant for the duration of the study,&#xD;
                  or who are breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Mitschke, BSc, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citruslabs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Renner, BSc, MSc</last_name>
    <phone>4242450284</phone>
    <email>hello@citruslabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Citruslabs</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Renner, BSc, MSc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

